GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab

GeNeuro announced the recruitment of first patients in its Phase II trial evaluating temelimab against long-COVID at the Geneva University Hospitals post-COVID clinic, as well as in all the other Swiss clinical centres participating to the study.